About
Nanoparticles
Areas of Focus
Categories
NanotechSmall Molecule PharmaceuticalNJ, NY, PA
Team (6)
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
458
By Phase
PHASE3: 1PHASE2: 1PHASE1: 1
By Status
COMPLETED: 2RECRUITING: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06790966Lead Sponsor
Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
PHASE3Recruiting
351 participants
Started: May 30, 2025 · Completed: Feb 28, 2029
NCT04260126Lead Sponsor
Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC
PHASE2Completed
95 participants
Started: Mar 29, 2021 · Completed: May 14, 2025
NCT02065973Lead Sponsor
An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101
PHASE1Completed
12 participants
Started: Feb 28, 2014 · Completed: Dec 30, 2015
Locations (1)
Headquarters
Princeton, NJ, United States
Map
Loading map...